Literature DB >> 2242521

A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.

U Elkayam1, J Amin, A Mehra, J Vasquez, L Weber, S H Rahimtoola.   

Abstract

We performed a prospective, randomized, double-blind, crossover study to compare the efficacy and safety of vasodilation with the calcium entry blocker nifedipine with that of isosorbide dinitrate (ISDN) and their combination as treatment for heart failure. Twenty-eight patients with New York Heart Association Functional class II or III chronic heart failure due to left ventricular systolic dysfunction were studied. All patients were maintained on a constant dose of digitalis and diuretics throughout the study. Eight weeks of therapy with nifedipine alone or in combination with ISDN resulted in a significantly higher incidence of heart failure deterioration necessitating hospitalizations and/or additional diuretics. Twenty-four percent of patients required hospitalization during nifedipine therapy and 26% required hospitalization during nifedipine-ISDN combination therapy in comparison to 0% requiring hospitalization during ISDN therapy alone. The total number of heart failure-worsening episodes was nine among patients on nifedipine, three among patients on ISDN (p less than 0.09 versus nifedipine), and 21 among patients on nifedipine-ISDN combination (p less than 0.001 versus nifedipine, p less than 0.0001 versus ISDN). Premature discontinuation of drug administration due to clinical deterioration or other side effects occurred in 29% of patients during nifedipine therapy, 5% of patients during ISDN therapy (p = 0.05 versus nifedipine), and 19% of patients during the combination therapy. A comparison of eight patients who demonstrated clinical deterioration on nifedipine with the remainder of the patients demonstrated no significant difference in left ventricular ejection fraction (0.24 +/- 0.06 versus 0.23 +/- 0.07) or maximal oxygen uptake during exercise (13 +/- 3 versus 14 +/- 2 ml/kg/min).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242521     DOI: 10.1161/01.cir.82.6.1954

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  50 in total

1.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 2.  The L-type calcium channel in the heart: the beat goes on.

Authors:  Ilona Bodi; Gabor Mikala; Sheryl E Koch; Shahab A Akhter; Arnold Schwartz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Predicting survival in heart failure.

Authors:  Viorel G Florea; Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

Review 4.  Treating hypertension in older adults: safety considerations.

Authors:  Wilbert S Aronow
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.

Authors:  P Milberg; M Fink; C Pott; G Frommeyer; J Biertz; N Osada; J Stypmann; G Mönnig; M Koopmann; G Breithardt; L Eckardt
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 6.  Outpatient management of congestive heart failure.

Authors:  E K Massin
Journal:  Tex Heart Inst J       Date:  1998

Review 7.  Evolving therapeutic concepts and imaging in ischemic cardiomyopathy.

Authors:  A Lahiri; R Senior
Journal:  J Nucl Cardiol       Date:  1998 Nov-Dec       Impact factor: 5.952

Review 8.  Community management of heart failure.

Authors:  R S McKelvie
Journal:  Can Fam Physician       Date:  1998-12       Impact factor: 3.275

Review 9.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 10.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.